METRONIDAZOLE
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Nov 1983
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
METRONIDAZOLE by Abbott is clinical pharmacology absorption disposition of metronidazole in the body is similar for both oral and intravenous dosage forms. Approved for the treatment of asymptomatic t, the treatment of acute intestinal amebiasis (amebic dysentery), amebic liver abscess and 1 more indications. First approved in 1983.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Metronidazole is a small-molecule nitroimidazole antibiotic with bactericidal activity against anaerobic bacteria and trichomonacidal activity. It is used to treat serious infections caused by susceptible anaerobic bacteria, asymptomatic trichomoniasis, acute intestinal amebiasis, and amebic liver abscess. The drug works by disrupting anaerobic microbial DNA and protein synthesis, with peak plasma concentrations achieved within 1.4–1.6 hours.
LOE Approaching
Product is nearing loss of exclusivity with moderate competitive pressure (30%), signaling potential team contraction and shift toward defensive positioning or exit strategies.
Mechanism of Action
CLINICAL PHARMACOLOGY Absorption Disposition of metronidazole in the body is similar for both oral and intravenous dosage forms. FLAGYL 375 capsules have been shown to have a rate and extent of absorption similar to metronidazole tablets (FLAGYL) and were bioequivalent at an equal single dose of…
Worked on METRONIDAZOLE at Abbott? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.